P-BCMA-101 Shows Early Effectiveness in First Multiple Myeloma Patients Treated in Phase 1 Trial
P-BCMA-101, Poseida Therapeutics’ CAR T-cell therapy, is safe and…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Seattle Genetics’ Investigational Therapy Fares Well in Multiple Myeloma Animal Models
A new antibody targeting the BCMA protein — called…
Screening for Multiple Myeloma Precursor Could Cut Deaths from the Cancer, Study Finds
Screening people with a family history of a multiple myeloma…
China FDA Prepares to Review Evomela for Approval in Multiple Myeloma Treatment
Multiple myeloma patients in China may soon have…
Multiple Myeloma Research Foundation Awards $7 Million to Accelerate Precision Immunotherapies for Myeloma Patients
As part of its $15 million Immunotherapy Initiative, the…
